Objective: As anti-amyloid therapeutic interventions shift from enrolling patients with Alzheimer's disease (AD) dementia to individuals with pre-clinical disease, the need for sensitive measures that allow for non-invasive, fast, disseminable, and cost-effective identification of preclinical status increases in importance. The recency ratio (Rr) is a memory measure that relies on analysis of serial position performance, which has been found to predict cognitive decline and conversion to early mild cognitive impairment (MCI). The aim of this study was to test Rr's sensitivity to cerebrospinal fluid (CSF) levels of the core AD biomarkers in individuals with MCI-AD and controls.
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Methods: Baseline data from 126 (110 controls and 16 MCI-AD) participants from the Wisconsin Alzheimer's Disease Research Center were analysed. Partial correlations adjusting for demographics were carried out between CSF measure of amyloid beta (Aβ40, Aβ42, and the 40/42 ratio) and tau (total and phosphorylated), and memory measures (Rr, delayed recall, and total recall) derived from the Rey's Auditory Verbal Learning Test.
Results: Results indicated that Rr was the most sensitive memory score to Aβ42 levels in MCI-AD, while no memory score correlated significantly with any biomarker in controls.
Conclusions: This study shows that Rr is a sensitive cognitive index of underlying amyloid β pathology in MCI-AD.
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The recency ratio (Rr) words-last few learned) is higher relative to earlier presented information, and to controls, whereas (2) the delayed recall of recency words is usually very poor. 4 Therefore, we postulated that the ratio between immediate and delayed recency would be higher in individuals with more AD pathology. Consistent with this assertion, we have shown that higher (ie, worse) Rr scores predict subsequent cognitive decline 1 and are linked with greater risk of preclinical (early) mild cognitive impairment (MCI). 3 Moreover, initial, unpublished evidence suggests Rr scores are substantially higher in AD than in other types of dementia, such as dementia with Lewy bodies. 5 However, the relationship between Rr and AD biomarkers is yet to be examined.
In the current study, we set out to test the hypothesis that Rr is sensitive to conventional biomarkers of AD by assessing the relation- including increases in neurofibrillary tangles formation, and synaptic and neuronal degeneration. Unlike with tau, CSF Aβ42 levels are reduced when the amyloid burden is higher in the brain, 9 probably due to reduced clearance. Therefore, we would expect a cognitive marker sensitive to early AD pathology would be associated with lower CSF Aβ42 levels, indicating increased amyloid load in the brain.
In contrast, a cognitive marker sensitive to progressed disease burden would measure neuronal dysfunction and tau dysmetabolism that may relate to neurodegeneration and tangle formation, ie, CSF T-tau and Ptau levels. We also examined whether Rr showed a stronger relationship with CSF markers than either traditional AVLT summary score (total recall across learning trials and delayed recall).
To test whether Rr was sensitive to AD biomarkers, we carried out cross-sectional analyses using data obtained from the University Alzheimer's Association criteria of early cognitive deficits on path to AD, without reaching the threshold for a full diagnosis of dementia. 10 Overall, 110 individuals were controls, and 16 participants had MCI-AD.
| Aβ and tau
CSF Aβ40 and Aβ42 levels were measured using the MSD Abeta Triplex assay (Meso Scale Discovery, Rockville, MD), as described by the manufacturer. Tau levels were analyzed using commercially available enzyme-linked immunosorbent assay methods (INNOTEST assays, Fujirebio, Ghent, Belgium). All analyses were performed by board-certified laboratory technicians blinded to clinical information.
| Procedure
Lumbar punctures for CSF collection were performed by trained clini- 
| Recency ratio
Recency was defined as the last four items presented in the AVLT word list. Rr was calculated by dividing the recency scores in the first recall test (trial 1 of the AVLT), by the corresponding scores in the very last recall test (delayed trial). An Rr score was calculated for each participant. As customary, 3 a correction was applied ((immediate recency score + 1) / (delayed recency score + 1)) to avoid missing data due to zero scores.
| Design and analysis
Partial bivariate Pearson's correlations, controlling for age, years of education, and gender, were carried out separately for the controls and individuals with MCI-AD. Correlated variables were (natural log)
transformed Rr, the AVLT total recall score, the AVLT delayed recall score, and (natural log) transformed Aβ40, Aβ42, the 40/42 ratio, T-, and P-tau, all of which distributed normally or close to it.
Bootstrapping (1000 samples) was also performed, and false discovery rate (FDR) 11 P-values were calculated for each set of analyses (controls and MCI-AD) separately to control for multiple tests.
3 | RESULTS Table 1 reports demographics data for the study participants. Participants with MCI-AD were generally older and performed more poorly at memory tests. CSF Aβ42 levels and ratio scores were lower and higher, respectively, in individuals with MCI-AD, suggesting increased brain amyloid load. However, although T-tau was higher in individuals with MCI-AD, P-tau was not, despite high correlations between T-and P-tau in both participants groups (R ≥ 0.890). Table 2 for partial correlation coefficients, P-values, FDR-adjusted P-values, and bootstrapped 95% confidence intervals.
| MCI-AD group

| Cognitively intact group
In cognitively unimpaired controls, correlation coefficients were much smaller than in the MCI-AD group, and none of the relationships between memory and CSF measures were significant after adjusting for age, education, and sex (P > 16; see Table 2 ).
TABLE 1
Demographics. N = number of participants included in the analysis who were either cognitively normal or had a diagnosis of MCI-AD; age in years (mean, standard deviation, and range); gender (number of females and percentage); education in years (mean, standard deviation, and range); Aβ40, Aβ42, Aβ40/42 ratio, total tau (T-tau) and hyperphosphorylated tau (P-tau) (means and standard deviations in pg/mL); AVLT total recall score (mean and standard deviation); AVLT delayed recall score (mean and standard deviation); and Rr score (mean and standard deviation). The analyses were carried out using natural log-transformed scores. Figure 1 depicts the correlations between CSF Aβ42 (adjusted for age, education, and sex) and log-transformed Rr in MCI-AD and controls.
| Rr and adjusted CSF Aβ42 in both groups
Notably, MCI-AD subjects tend to cluster around higher Rr scores and lower CSF Aβ42 levels, respectively, consistent with the differences reported in Table 1 . We also report the same plot with T-tau for comparison.
| DISCUSSION
The results of the cross-sectional analysis on baseline data, collected from participants enrolled in the Wisconsin ADRC Clinical Core, show that Rr is a sensitive measure of CSF Aβ42 levels in individuals with MCI-AD, performing significantly better than standard neuropsychological measures of memory, such as AVLT total and delayed recall.
In contrast, no memory score was sensitive to CSF Aβ42 levels in controls, nor any score correlated significantly with Aβ40, the 40/42 ratio, T-or P-Tau levels in either cohort.
The basis for the association between Rr and CSF Aβ42 is not known. Increased amyloid burden in AD tends to develop first in default mode network (DMN) areas, leading to reduced connectivity within these areas, and between the DMN and the frontoparietal network. 12 In contrast, early tau pathology has been detected primarily in the medial temporal lobe. 13 Therefore, it is possible that Rr may be sensitive to the adverse effects of early brain amyloid deposition, and specifically as it affects connectivity in and around the DMN. It is also to note that increases in Amyloid β oligomers and deposition A clear limitation of this study is the low sample size in the MCI-AD group, which totalled at 16 individuals. Additionally, brain AD biomarkers were not examined. Nonetheless, further research is needed to confirm these findings. Another possible limitation is that the time interval between CSF and cognitive measurements was roughly 2 months. While cognitive ability is not expected to change significantly during such a short time period, as cognitive change, even in MCI-AD, is expected to be rather slow, CSF biomarkers may turn over faster than 2 months. However, there is typically more concern about diurnal shifts in CSF proteins than month to month changes, 19 and it is generally accepted that changes in CSF biomarkers levels reflecting brain changes will also progress slowly. Therefore, 2 months should represent a broadly acceptable interval length.
Recency ratio represents a non-invasive, cost-effective, rapid, and accessible test, which can be easily calculated from common neuropsychological test batteries of recall performance, including the AVLT, as long as learning items are not semantically related. Due to its sensitivity to CSF Aβ42 levels in MCI-AD, as well as its usefulness to predict pre-clinical MCI (3) and CSF glutamatergic abnormalities (2), we recommend that it is considered as part of screening batteries for early-stage therapeutic trials in AD. Moreover, as we have argued in the past, we recommend that serial position data for recall tests are included in databases for the study of AD and neurodegeneration.
